Raynaud's phenomenon
- PMID:17218139
- DOI: 10.1016/j.jbspin.2006.07.002
Raynaud's phenomenon
Abstract
Vascular acrosyndromes constitute a common reason for physician visits. They are associated with connective tissue disease; for example, 90% of patients with scleroderma experience Raynaud's phenomenon. The rheumatologist must strive to establish the diagnosis, to identify a potential underlying cause, and to prescribe effective treatment when the symptoms are incapacitating. Raynaud's phenomenon is the acrosyndrome most commonly encountered by rheumatologists. The diagnosis of Raynaud's phenomenon rests on clinical grounds. Nailfold capillaroscopy and immunological tests are useful chiefly for determining the cause. Calcium-channel antagonists are the treatment of reference for Raynaud's phenomenon. Drugs introduced over the last few years for severe refractory forms include prostacyclin and its derivatives, endothelin receptor antagonists, and phosphodiesterase inhibitors. These drugs were developed as a result of new knowledge on the pathogenesis of Raynaud's phenomenon. Acrocyanosis, which is extremely common, and erythromelalgia are the other main vascular acrosyndromes.
Similar articles
- Recent achievements in the management of Raynaud's phenomenon.Baumhäkel M, Böhm M.Baumhäkel M, et al.Vasc Health Risk Manag. 2010 Apr 15;6:207-14. doi: 10.2147/vhrm.s5255.Vasc Health Risk Manag. 2010.PMID:20407628Free PMC article.Review.
- Diagnosis and management of Raynaud's phenomenon.Goundry B, Bell L, Langtree M, Moorthy A.Goundry B, et al.BMJ. 2012 Feb 7;344:e289. doi: 10.1136/bmj.e289.BMJ. 2012.PMID:22315243Review.No abstract available.
- [Raynaud's phenomenon].Zeni S, Ingegnoli F.Zeni S, et al.Reumatismo. 2004 Apr-Jun;56(2):77-81.Reumatismo. 2004.PMID:15309214Review.Italian.
- [Primary and secondary Raynaud's phenomenon].Distler JH.Distler JH.Z Rheumatol. 2008 May;67(3):211-7; quiz 218-9. doi: 10.1007/s00393-008-0282-9.Z Rheumatol. 2008.PMID:18437399German.
- Understanding, assessing and treating Raynaud's phenomenon.Boin F, Wigley FM.Boin F, et al.Curr Opin Rheumatol. 2005 Nov;17(6):752-60. doi: 10.1097/01.bor.0000179944.35400.6e.Curr Opin Rheumatol. 2005.PMID:16224254Review.
Cited by
- The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ.Kirkby NS, et al.Br J Pharmacol. 2008 Mar;153(6):1105-19. doi: 10.1038/sj.bjp.0707516. Epub 2007 Oct 29.Br J Pharmacol. 2008.PMID:17965745Free PMC article.Review.
- Effect of Korean red ginseng on cold hypersensitivity in the hands and feet: study protocol for a randomized controlled trial.Park KS, Kim JW, Jo JY, Hwang DS, Lee CH, Jang JB, Lee KS, Yeo I, Lee JM.Park KS, et al.Trials. 2013 Dec 19;14:438. doi: 10.1186/1745-6215-14-438.Trials. 2013.PMID:24354675Free PMC article.Clinical Trial.
- The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients.Rosato E, Borghese F, Pisarri S, Salsano F.Rosato E, et al.Clin Rheumatol. 2009 Dec;28(12):1379-84. doi: 10.1007/s10067-009-1251-7. Epub 2009 Aug 20.Clin Rheumatol. 2009.PMID:19690939
- Chronic myelomonocytic leukemia presenting as upper limb gangrene.Priya UL, Abdulla MC, Umashankar P.Priya UL, et al.South Asian J Cancer. 2018 Oct-Dec;7(4):222. doi: 10.4103/sajc.sajc_16_18.South Asian J Cancer. 2018.PMID:30430087Free PMC article.No abstract available.
- Development and Validation of a Precise, Single HPLC Method for the Determination of Tolperisone Impurities in API and Pharmaceutical Dosage Forms.Raju TV, Seshadri RK, Arutla S, Mohan TS, Rao IM, Nittala SR.Raju TV, et al.Sci Pharm. 2013 Jan-Mar;81(1):123-38. doi: 10.3797/scipharm.1209-17. Epub 2012 Nov 5.Sci Pharm. 2013.PMID:23641333Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical